Advertisement

Drugs

, Volume 59, Issue 3, pp 401–410 | Cite as

What is New in the Treatment of Multiple Sclerosis?

  • Bianca Weinstock-Guttman
  • Lawrence D. Jacobs
Leading Article

Abstract

Multiple sclerosis (MS) is considered an autoimmune disease associated with immune activity directed against central nervous system antigens. Based on this concept, immunosuppression and immunomodualtion have been the mainstays of therapeutic strategies in MS. During the last decade new therapies have been shown to significantly improve MS disease course. The effective therapies have led to a better understanding of MS pathogenesis and further development of even more efficient therapeutic interventions.

Recombinant interferon (IFN)β represents the first breakthrough in MS therapy. Three large placebo-controlled, double-blind studies and several smaller studies have demonstrated the efficacy of different forms of IFNβ administrated by either subcutaneous or intramuscular routes and at different doses in patients with active relapsing-remitting multiple sclerosis (RR-MS). The three IFNβ drugs are IFNβ-1b and two IFNβ-1a preparations (Avonex® and Rebif®). Although each clinical trial had unique features and differences that make direct comparisons difficult, the aggregate results demonstrate a clear benefit of IFNβ for decreasing relapses and probability of sustained clinical disability progression in patients with RR-MS. All forms of IFNβ therapy had beneficial effects on the disease process measured by brain magnetic resonance imaging (MRI). IFNβ-1a (Avonex®) also showed benefit in slowing or preventing the development of MS related brain atrophy measured by MRI after 2 years of therapy.

Glatiramer acetate, the acetate salt of a mixture synthetic polypeptides thought to mimic the myelin basic protein showed a significant positive results in reducing the relapse rate in patients with RR-MS. Follow up of these patients for approximately 3 years continued to show a beneficial effect on disease relapse rate. Recent MRI data supported the beneficial clinical results seen with glatiramer acetate in patients with RR-MS.

Recent studies using intravenous immune globulin (IVIG) suggest that IVIG could be effective to some degree in patients with RR-MS. However, there is not enough evidence that IVIG is equivalent to IFNβ or glatiramer acetate in the treatment of patients with RR-MS.

There have also been recent therapeutical advances in secondary progressive MS (SP-MS). A recent large phase III, placebo-controlled study with IFNβ-1b in patients with SP-MS convincingly documented that IFNβ-1b slowed progression of the disease independent of the degree of the clinical disability at the time of treatment initiation and independent of presence of superimposed relapses.

Mitoxantrone, an anthracenedione synthetic agent, was also shown to be effective as treatment for active SP-MS. It is well tolerated but the duration of treatment is limited by cumulative cardiotoxicity.

There is a growing consensus that disease-modifying therapies should be initiated early in the course of the disease before irreversible clinical disability has developed. Different therapies should be considered and tailored based on patient condition. Combination therapies could be considered as a therapeutic option for patients that failed therapies with IFNβ and/or glatiramer acetate. Currently, there are new ongoing studies testing safety and/or efficacy of different combination regimens (i.e. azathioprine with IFNβ, IFNβ with glatiramer acetate, or pulses of intravenous cyclophosphamide with IFNβ).

Determining the effect of different therapies on the course of the disease within large clinical studies appears easier than determining individual responsiveness. Therefore, standardised methods for evaluating individual patients receiving disease-modifying therapies and development of effective therapeutic algorithms are needed.

Keywords

Multiple Sclerosis Mitoxantrone Expand Disability Status Scale Glatiramer Acetate Cladribine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993: 655-61Google Scholar
  2. 2.
    Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285–94PubMedCrossRefGoogle Scholar
  3. 3.
    Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis (PRISMS) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352(9139): 1498–504CrossRefGoogle Scholar
  4. 4.
    Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907–11PubMedCrossRefGoogle Scholar
  5. 5.
    Lucchinetti CF, Brack W, Rodriguez M, et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 1996; 6: 259–74PubMedCrossRefGoogle Scholar
  6. 6.
    Trap BD, Peterson J, Ransohoff RM, et al. Axonal transaction in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278–85CrossRefGoogle Scholar
  7. 7.
    Weinstock-Guttman B, Ransohoff RM, Kinkel RP, et al. The interferons: biological effects mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995; 37: 7–15PubMedCrossRefGoogle Scholar
  8. 8.
    Yong VW, Chabot S, Stuve O, et al. Interferon beta in the treatment of multiple sclerosis: mechanism of action. Neurology 1998; 51: 682–9PubMedCrossRefGoogle Scholar
  9. 9.
    Runkel L, Meier W, Pepinsky B, et al. Structural analysis of human interferon beta (IFNβ): studies addressing the activity differences between IFNβ-1a and IFNβ-1b [abstract P203]. Mult Scler 1997; 3: 337CrossRefGoogle Scholar
  10. 10.
    Alam J, McAllister A, Scaramucci J, et al. Pharmacokinetics and pharmacodynamics of interferon beta-1a in healthy volunteers after intravenous, subcutaneous and intramuscular administration. Clin Drug Invest 1997; 14(1): 35–43CrossRefGoogle Scholar
  11. 11.
    Munafo A, Trinchard-Lugan I, Nguyen TXQ, et al. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur J Neurol 1998; 5: 187–93PubMedCrossRefGoogle Scholar
  12. 12.
    Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268–76PubMedCrossRefGoogle Scholar
  13. 13.
    The IFNB Multiple Sclerosis Study Group, the UBC MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277–85CrossRefGoogle Scholar
  14. 14.
    Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon-β-1a for relapsing multiple sclerosis. Ann Neurol 1998; 43: 79–87PubMedCrossRefGoogle Scholar
  15. 15.
    European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491–7CrossRefGoogle Scholar
  16. 16.
    Rudick RA, Fisher E, Lee JC, et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS: Multiple Collaborative Research Group. Neurology 1999; 53(8): 1698–704PubMedCrossRefGoogle Scholar
  17. 17.
    Bornstein MB, Miller AI, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987; 317: 408–14PubMedCrossRefGoogle Scholar
  18. 18.
    Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability: Copolymer I Multiple Sclerosis Study Group. Neurology 1998; 50(3): 701–8PubMedCrossRefGoogle Scholar
  19. 19.
    Comi G, Filippi M, the Copaxone MRI study group. The effect of glatiramer acetate (Copaxone®) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis: a multi-center randomized, double-blind placebo-controlled study extended by open-label treatment. Neurology 1999; 52: A289Google Scholar
  20. 20.
    Fazekas F, Deisenhammer F, Strasser FS, et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis: Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997; 349: 589–93PubMedCrossRefGoogle Scholar
  21. 21.
    Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses. Neurology 1998; 50: 398–402PubMedCrossRefGoogle Scholar
  22. 22.
    Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50: 1273–81PubMedCrossRefGoogle Scholar
  23. 23.
    Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991; 38: 1051–5CrossRefGoogle Scholar
  24. 24.
    Mandler RN, Ahmed W, Dencoff JE. Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998; 51: 1219–20PubMedCrossRefGoogle Scholar
  25. 25.
    Moreau T, Blanc S, Riche G, et al. ERAZISMUS: Early Azathioprine versus Beta-Interferon Treatment in Multiple Sclerosis: results of a pilot safety study [abstract]. The 9th Annual Meeting of the European Neurological Society: 1999 Jun 5–9; Milan, 143Google Scholar
  26. 26.
    Goodkin DE, Rudick RA, VanderBrug Medendorp S, at al. Low dose (7.5mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995; 37: 30–40PubMedCrossRefGoogle Scholar
  27. 27.
    Hartung HP, Gonsette R, the MIMS-Study Group. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, randomized, observer-blind phase III trial: clinical results and three-year follow-up [abstract]. Neurology 1999; 52: A290Google Scholar
  28. 28.
    Sipe JC, Romine JS, Zozloi JA, et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994; 344: 9–13PubMedCrossRefGoogle Scholar
  29. 29.
    Patty D. Results of the 3-year, double blind, placebo-controlled study of interferon beta 1a (Rebif) in secondary-progressive multiple sclerosis. The 9th Annual Meeting of the European Neurological Society: 1999 Jun 5–9; MilanGoogle Scholar
  30. 30.
    Goodkin DE, Rudick RA, VanderBrug Medendorp S. Low-dose oral methotrexate in chronic progressive multiple sclerosis: analysis of serial MRIs. Neurology 1996; 47: 1153–7PubMedCrossRefGoogle Scholar
  31. 31.
    Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized, three arm study of high-dose intravenous cyclophosphamide, plasma exchange and ACTH. N Engl J Med 1983; 308: 173–80PubMedCrossRefGoogle Scholar
  32. 32.
    Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993; 43(5): 910–8PubMedCrossRefGoogle Scholar
  33. 33.
    The Canadian Cooperative Multiple Sclerosis Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337: 441–6Google Scholar
  34. 34.
    Weinstock-Guttman B, Kinkel RP, Cohen JA, et al. Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide. Neurologist 1997; 3: 178–85CrossRefGoogle Scholar
  35. 35.
    Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997; 244: 153–9PubMedCrossRefGoogle Scholar
  36. 36.
    Romine JS, Sipe JC, Koziol JA, et al. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 1999; 111: 35–44PubMedCrossRefGoogle Scholar
  37. 37.
    Rovaris M, Filippi M, Mastronardo G, et al. Assessment of Mylinax™ (cladribine) in patients with progressive MS: subgroup analysis of a phase III multicenter trial [abstract]. Neurology 1999; 52: A291CrossRefGoogle Scholar
  38. 38.
    Durelli L, Cocito D, Riccio A. High dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 1986; 36: 238–43PubMedCrossRefGoogle Scholar
  39. 39.
    Andersson PB, Goodkin DE. Glucocorticosteroid therapy for multiple sclerosis: a critical review. J Neurol Sci 1998; 160: 16–25PubMedCrossRefGoogle Scholar
  40. 40.
    Barnes D, Hughes RAC, Morris R, et al. Randomized trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997; 349: 902–6PubMedCrossRefGoogle Scholar
  41. 41.
    Beck RW, Cleary PA, Trobe J, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993; 329: 1764–9PubMedCrossRefGoogle Scholar
  42. 42.
    Goodkin DE, Kinkel RP, Weinstock-Guttman B, et al. A phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis. Neurology 1998; 51: 239–45PubMedCrossRefGoogle Scholar
  43. 43.
    US MS society urges early drug treatment. Scrip 1998 Oct 23; 2381: 21Google Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  1. 1.Buffalo General HospitalBuffalo General Hospital and Baird Center for Multiple Sclerosis at SUNY UniversityBuffaloUSA

Personalised recommendations